group IIC sPLA2 Inhibitors

Chemical inhibitors of group IIC sPLA2 provide a diverse array of mechanisms to impede its function. Indoxamod inhibits the enzymatic activity of this protein by directly occupying its catalytic site, preventing the hydrolysis of phospholipids essential for its biological activity. Similarly, Varespladib functions as a competitive inhibitor, binding to the active site of group IIC sPLA2, which blocks its interaction with substrate molecules. Darapladib also directly engages with the lipophilic channel of the enzyme, an approach that impedes the enzyme's ability to bind and hydrolyze its phospholipid substrates. Manoalide goes a step further by covalently modifying lysine residues at the enzyme's active site, thereby leading to a sustained inhibition of group IIC sPLA2's functional activity.

Further along the spectrum, Methyl arachidonyl fluorophosphonate and Bromoenol lactone (BEL) act by irreversibly binding to the serine residue and the active site of group IIC sPLA2, respectively. This binding leads to an enduring blockage of enzymatic activity. The compound MJ33 engages the catalytic domain of the enzyme, preventing the enzymatic cleavage of phospholipids. Rosiglitazone, although an indirect inhibitor, impacts group IIC sPLA2 by activating PPARγ which leads to a reduction in the enzyme's activity. CAY10502, similar to other competitive inhibitors, occupies the catalytic site and impedes the enzyme's ability to process substrates. PACOCF3 also inhibits group IIC sPLA2 by covalently modifying the active site, which effectively reduces lipid hydrolysis, a key function of the group IIC sPLA2 enzyme. These chemical inhibitors collectively demonstrate a robust approach to halting the activity of group IIC sPLA2 by targeting its active site or by altering its substrate interactions.